BIOBV Biohit Oyj Series B

Chief Medical Director Kari Syrjänen will retire from Biohit Oyj

Chief Medical Director Kari Syrjänen will retire from Biohit Oyj



Biohit Oyj 31.12.2018 12:00



Biohit’s management team member Chief Medical Director Kari Syrjänen will retire as planned 31st of December 2018. Kari Syrjänen has been employed by Biohit since 2013.

”I would like to thank Kari for the excellent work during these years”, says Semi Korpela, President and CEO of Biohit.



Additional information:

CEO Semi Korpela, Biohit Oyj

tel.

  

Biohit Oyj in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission ‘Innovating for Health’ means that we provide innovative products and services to promote research and early diagnostics. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares (BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare.



EN
31/12/2018

Underlying

BIOBVBiohit Oyj Series B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biohit Oyj Series B

 PRESS RELEASE
Free
BIOBV Biohit Oyj Seri...

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2019

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2019 Biohit Oyj Half Year Financial Report 14 August 2019 at 9:30 am local time (EET) SUMMARY January-June 2019 Net sales EUR 5.0 million (EUR 4.9 million) Net sales grew by 1% compared to H1/2018Operative EBITDA EUR +0.4 million (EUR -0.1 million)*Cash at the end of the period EUR 1.3 million (EUR 1.3 million)Net sales from international operations 95.5% (97.2%) of total net salesEquity ratio 85.9% (89.4%)** * Biohit Group implemented the IFRS 16 Leases -standard effective from 1 January 2019. This impacts on Operative EBITDA +0.1 million...

August 14, 2019 1 EN
 PRESS RELEASE
Free
BIOBV Biohit Oyj Seri...

Two clinical trials with Acetium® capsule for prevention of migraine-...

Two clinical trials with Acetium® capsule for prevention of migraine-type headache have been concluded Biohit Oyj Stock Exchange Release August 9th 2019 at 15.30 pm local time (EET) In 2014, Biohit Oyj initiated two clinical trials for prevention of migraine-type headache attacks, testing the efficacy of Acetium® capsule. Because of a slow patient enrollment, the trial was subsequently extended to two additional clinical centers abroad.  Despite this extension, the originally planned cohort size was not completely reached. In the whole series, Acetium® failed to show an efficacy st...

August 9, 2019 1 EN
 PRESS RELEASE
Free
BIOBV Biohit Oyj Seri...

Biohit Oyj B-shares Subscribed with Stock Options I 2013

Biohit Oyj B-shares Subscribed with Stock Options I 2013 Biohit Oyj Stock Exchange Release June 12, 2019 at 13.15 a.m. (EEST) A total number of 88,552 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 12 February 2019 and 31 May 2019. These shares have been entered into the Trade Register on June 12, 2019, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on NASDAQ Helsinki as of June 13, 2019 together with the existing B-shares. The share subscription price was EUR 2.2766 p...

June 12, 2019 1 EN
 PRESS RELEASE
Free
BIOBV Biohit Oyj Seri...

Biohit Plc - Managers' transactions - Söderström

Biohit Plc - Managers' transactions - Söderström Person subject to the notification requirementName: Söderström, DanielaPosition: Other senior managerIssuer: Biohit PlcLEI: 74370089ATTSNBXJVT29      Notification type: INITIAL NOTIFICATIONReference number: 74370089ATTSNBXJVT29_20190603065401_4             Transaction date: 2019-05-29Instrument type: SHAREISIN: FI0009005482Nature of the transaction: SUBSCRIPTION(X) Linked to stock option programme Transaction details(1): Volume: 25 000 Unit price: 2.2766 EUR Aggregated transactions(1): Volume: 25 000 Volume weighted average price: 2.2766 ...

June 3, 2019 1 EN
 PRESS RELEASE
Free
BIOBV Biohit Oyj Seri...

Notice of Biohit Oyj’s Annual General Meeting

Notice of Biohit Oyj’s Annual General Meeting Notice of Biohit Oyj’s Annual General Meeting Biohit Oyj Stock Exchange Release March 29, 2019 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held on Wednesday, April 24, 2019 starting at 5:00 pm at hotel Crowne Plaza. The address is Mannerheimintie 50, 00260 Helsinki. The reception of shareholders registered for the meeting and the distribution of voting slips will commence at 4:00 pm. Coffee will be served. A. Matters on the agenda of the Annual General M...

March 29, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch